DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Hurvitz SA, Andre F, Jiang Z et al.
Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1. San Antonio Breast Cancer Symposium 2014; S6-01.
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.